| Name | 4D Pharma |
|---|---|
| Epic | DDDD |
| Isin | GB00BJL5BR07 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 16.66p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £30.04 | Debt ratio | n/a |
| Shares in issue | 180.34 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -292.29 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -31.83 | 52-week high / low | 16.66p / 16.66p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | 4D Pharma |
|---|---|
| Address | Third Floor, 9 Bond Court, Leeds, LS1 2JZ |
| Telephone | +44 (0) 161 837 6205 |
| Website | http://www.4dpharmaplc.com |
| Director | Position |
|---|---|
| Mr Duncan Joseph Peyton | CEO |
| Mr Paul Maier | Non-Executive Director |
| Professor Axel Glasmacher | Non-Executive Chairman |
| Mr Katrin Rupalla | Independent Non-Executive Director |
| Mr Sandy Macrae | Independent Non-Executive Director |
| Mr Ed Baracchini | Independent Non-Executive Director |
| Mr Alexander James Stevenson | Chief Scientific Officer |
| Assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Reporting date | 31/12/21 | 31/12/20 | 31/12/19 |
| Intangible asssets and goodwill | 13.69 | 14.03 | 13.99 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 17.45 | 18.7 | 19.34 |
| Inventory / work in progress | 0.27 | 0.29 | 0.2 |
| Trade and other receivables | 2.17 | 3.22 | 1.12 |
| Cash and equivalents | 15.5 | 8.78 | 3.84 |
| Other current assets and asset held for resale | 7.56 | 4.44 | 6.12 |
| Total of all assets | 42.94 | 35.42 | 30.61 |
| Liabilities £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Short term liabilities | 4.89 | 6.45 | 6.26 |
| Long term liabilities | 14.85 | 1 | 2.01 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 19.74 | 7.45 | 8.27 |
| Net assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Net assets | 23.2 | 27.97 | 22.34 |
| Equity £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Share capital | 0.45 | 0.33 | 0.16 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -166.61 | -112.78 | -87.02 |
| Share premium account | 185.7 | 136.28 | 108.3 |
| Total equity | 23.2 | 27.97 | 22.34 |
| Income £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -70.48 | -30.18 | -28.97 |
| Pre-tax profit | -57.47 | -30.35 | -29.43 |